Testing Biejia-Ruangan compound after liver cancer removal
Part of Cancer, Digestive system clinical trials.
This trial tests a Chinese herbal compound to see if it helps people with liver cancer stay cancer-free longer after surgery or ablation. It is for patients with hepatitis B-related liver damage who have had their tumor completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have chronic hepatitis B with liver scarring (fibrosis or cirrhosis).
- You were diagnosed with early-stage liver cancer (stages Ia to IIa) and had surgery or heat ablation to remove it.
- It has been 8 to 12 weeks since your procedure, and scans show no cancer left.
- Your liver function is good enough (Child-Pugh score A or B).
- You have not had other cancer treatments like chemotherapy or radiation before this surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a traditional Chinese medicine called Fufang Biejiaruangan, taken with standard antiviral drugs, can lower the risk of liver cancer in people with hepatitis B-related cirrhosis. Participants will be randomly assigned to receive the medicine or a placebo to see if it helps prevent liver cancer.
This trial tests whether Babao Dan, a traditional Chinese medicine capsule, combined with antiviral drugs can reduce the risk of liver cancer in people with hepatitis B-related cirrhosis (advanced liver scarring). The study aims to see if this combination helps protect your liver and prevent cancer development.
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.